About us

Focusing on breakthrough innovation that benefits patients

We are a pioneering, clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease.

Our initial therapeutic focus is in oncology, where pivotal clinical trials are currently underway for our lead program, tebentafusp (IMCgp100), as a potential treatment for metastatic uveal melanoma, a rare form of eye cancer.

We also have a robust pipeline of programs spanning a broad range of cancer indications, as well as infectious and autoimmune diseases.

Our science

Video

ImmTAC® molecules in action

Our story

2019

Immunocore opens an office in the BioHealth Capital Region of Rockville, Maryland.

2019

Immunocore Board appoints Bahija Jallal as Chief Executive Officer.

2018

Partnership with Genentech to expand existing discovery collaboration to co-develop Immunocore's therapeutic candidate IMC-C103C.

2018

Immunocore's second ImmTAC molecule, IMCnyeso, enters Phase I clinical trials.

2017

Immunocore announces a collaboration and investment from the Bill and Melinda Gates Foundation to accelerate the development of ImmTAV® and ImmTAB® technology for the treatment of infectious diseases.

2017

Immunocore announces significant laboratory expansion at Milton Park, Oxfordshire.

2016

IMCgp100 is granted Orphan Drug Designation by the FDA for the treatment of uveal melanoma.

2016

IMCgp100, durvalumab and tremelimumab combination trial is initiated with AstraZeneca's biologics R&D unit for treatment of metastatic cutaneous melanoma.

2015

IMCgp100 is accepted for the EMA's adaptive pathway pilot program.

2015

Immunocore opens a US office in Philadelphia.

2015

Immunocore wins 'Biotech of the Year' at the Scrip awards. The Scrip Awards seek to applaud the essential role that the pharmaceutical, biotech and other allied industries play in improving healthcare.

2014

Immunocore partners with Eli Lilly to research, co-discover and co-develop novel therapies.

2013

Immunocore initiates a Phase II clinical trial for IMCgp100 in melanoma.

2013

Immunocore establishes partnerships with GSK, Genentech & AstraZeneca to discover and develop novel cancer targets.

2010

Immunocore launches its first clinical trial for IMCgp100 in malignant melanoma.

2008

With the help of private investment, the technology is brought back in-house and two sister companies are founded; Immunocore focusing on soluble TCR technology and Adaptimmune focusing on cellular TCR therapy.

2006

Avidex is acquired by Medigene AG.

1999

Dr Bent Jakobsen founded Avidex as a spin-off company from his research into T cell receptors at the University of Oxford.

Our vision

At Immunocore, we believe we are TCR pioneers with a passion to transform patients' lives and a goal to deliver new medicines. We will implement this bold vision by following our values.

Our values

1

We lead with science to benefit patients

We work together to set clear priorities and objectives aligned to the organisation’s goals, to create an environment that maximises individual contributions that will benefit patients.

2

We are entrepreneurial

We are drawn to opportunities to seek out key areas of improvement; we ask questions, voice opinions and take initiative to get things done.

3

We value diversity to drive innovation

We value and listen to all views and opinions. Our success is dependent on pushing boundaries, utilizing diverse skills and approaches to foster creative thinking.

4

We respect and trust each other

We respect and trust each other with good intentions and are consistent and fair as to how we treat others. We foster transparent and frequent communication.

5

We act with integrity

We act with integrity taking responsibility for our actions and challenge actions or decisions we believe to be wrong. We take decisions to improve the success of the organisation.